Elsevier

Advances in Medical Sciences

Volume 61, Issue 2, September 2016, Pages 207-211
Advances in Medical Sciences

Original Research Article
Dithranol treatment of plaque-type psoriasis increases serum TNF-like weak inducer of apoptosis (TWEAK)

https://doi.org/10.1016/j.advms.2016.01.001Get rights and content

Abstract

Purpose

TNF-like weak inducer of apoptosis (TWEAK) mediates not only apoptosis, but also inflammation, cell growth and angiogenesis. The role of TWEAK in psoriasis remains unknown. The aim of the study was to assess serum levels of TWEAK in psoriatic patients before and after topical treatment with dithranol in relation to the clinical activity of the disease.

Material and methods

Serum samples were collected from 40 patients with plaque type psoriasis before and after topical treatment with dithranol. The concentrations of serum TWEAK were measured by ELISA and next compared with 16 healthy controls. The data were analyzed with respect to Psoriasis Area and Severity Index (PASI).

Results

Baseline serum TWEAK concentrations of psoriatic patients (685 ± 166 pg/ml) were significantly greater compared to healthy controls (565 ± 110 pg/ml). Topical treatment resulted in further increase in serum TWEAK (749 ± 179 pg/ml; p < 0.01). In case of patients with initial serum TWEAK concentrations above the median, PASI after topical treatment was lower compared to the individuals with initial TWEAK below the median.

Conclusion

According to the study, serum Tweak was increased in psoriasis patients compared with controls. Moreover, dithranol topical treatment caused further increase in serum TWEAK. Also, a higher effectiveness of topical treatment was observed in case of patients with higher initial TWEAK concentrations. The results suggest a potential role of TWEAK in psoriasis therapy.

Introduction

Psoriasis is a common chronic inflammatory disorder with prevalence ranging from 0.1% to 11.0% in different populations [1]. The etiology of the disease is multifactorial and not fully known. According to recent suggestions, epidermal keratinocyte hyperproliferation and incomplete differentiation result from T-cell mediated autoimmune reaction [2], [3]. The disease is characterized by the coincidence of infiltration of the dermis with multiple immune cells and increased dermal vascularity. Angioproliferation seems to play a crucial role in the early stages of the development of psoriatic lesions [4]. Laporte et al. [5] demonstrated that spontaneous keratinocyte apoptosis is decreased in lesional skin in psoriasis. They suggested that this phenomenon could play a role in the induction of psoriatic hyperplasia. Moreover, psoriatic keratinocytes are extremely resistant to apoptosis compared with normal skin-derived keratinocytes [6].

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) was first described as a member of the tumor necrosis factor (TNF) superfamily in 1997 by Chicheportich [7]. The authors reported its ability of inducing apoptosis. TWEAK is a transmembrane protein which can be cleaved to generate a smaller, active form and become a cytokine. In physiologic conditions, by binding to its receptor (fibroblast growth factor-inducible 14 – Fn14), TWEAK can participate in tissue repair and regeneration after acute injury [8]. In chronic inflammatory conditions, the TWEAK/Fn14 pathway promotes chronic inflammation [7], pathological hyperplasia and angiogenesis [9]. Girgenrath et al. [8] demonstrated that TWEAK promoted proliferation of progenitor cells and inhibited their terminal differentiation. All of these disturbances can be observed in psoriatic skin lesions.

Dithranol (anthralin) is a successful method of treatment of exacerbated plaque psoriasis. Although it is one of the oldest available therapies for psoriasis, very little data on its mechanism of action can be found. Recently, it has been shown to exert its therapeutic effect by inducing keratinocyte apoptosis [10].

The data on the role of serum TWEAK in psoriasis are very limited. The aim of this study was to compare serum concentrations of TWEAK in psoriatic patients and in healthy control group. We also investigated the influence of topical treatment with dithranol on serum TWEAK concentrations and their relationship with clinical disease activity measured with PASI (Psoriasis Area and Severity Index).

Section snippets

Patients

The study was carried out on 40 patients aged 18 to 84 with exacerbated plaque psoriasis, characterized in Table 1. The individuals with other types of psoriasis were excluded from the study. Neither topical nor systemic treatment for psoriasis had been used by the patients for a period ranging from 1 to several months. During the study all the patients were treated topically: initially with 5% salicylic acid ointment (until desquamation – a few days), followed by dithranol in three increasing

Results

We observed an over two-fold decrease in PASI following the treatment (Table 1) (p < 0.001). Baseline serum TWEAK concentrations (from 359 pg/ml to 984 pg/ml, median 668 pg/ml) were significantly higher than those in the healthy controls (from 329 pg/ml to 738 pg/ml, median 573) (Fig. 1). Topical treatment caused further increase in serum TWEAK (p < 0.001) (Fig. 1).

We observed a significant positive correlation between PASI and patients’ white blood cells (WBC) count, as well as between TWEAK

Discussion

In the present study we have demonstrated significantly increased serum TWEAK levels in patients with psoriasis compared with healthy subjects. High levels of TWEAK in exacerbated psoriasis can reflect its possible role in the pathogenesis of the disease. Increased serum TWEAK levels had been previously reported in psoriatic arthritis [17].

TWEAK is a multifunctional cytokine that has been reported to play an important role in many inflammatory disorders including Henoch–Schoenlein–purpura [13],

Conclusion

In the present study we demonstrated significantly increased serum levels of TWEAK in patients with exacerbated plaque psoriasis compared to the control group. After topical treatment with dithranol, the concentration of serum TWEAK increased even further, as compared to baseline. Our results indicate a potential dual role of TWEAK: a proliferation inducing effect in lower concentrations and a proapoptotic effect in high concentrations. Better results of topical treatment in psoriatic patients

Conflicts of interests

The authors declare no conflict of interests.

Financial disclosure

The study was supported by grant (113-49733) from Medical University of Bialystok, Poland.

References (26)

  • M. Laporte et al.

    Apoptosis in established and healing psoriasis

    Dermatology

    (2000)
  • T. Wrone-Smith et al.

    Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared to normal skin

    Am J Pathol

    (1997)
  • M. Girgenrath et al.

    TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration

    EMBO J

    (2006)
  • Cited by (0)

    View full text